Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity

被引:79
|
作者
Liu, K [1 ]
Rosenberg, SA [1 ]
机构
[1] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源
JOURNAL OF IMMUNOLOGY | 2001年 / 167卷 / 11期
关键词
D O I
10.4049/jimmunol.167.11.6356
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IL-2-dependent activated cells undergo apoptotic death when IL-2 is withdrawn either in vitro or after in vivo cell transfer. To attempt to sustain their survival after IL-2 withdrawal, melanoma reactive human T lymphocytes were retrovirally transduced with an exogenous human IL-2 gene. Transduced PBMC and cloned CD8(+) T cells produced IL-2 and maintained viability after IL-2 withdrawal. Upon restimulation, IL-2 transductants proliferated in the absence of exogenous IL-2 and could be actively grown, and their survival could be maintained without added IL-2 for over 8 wk. PBMCs similarly transduced with a control vector did not produce IL-2 and failed to proliferate in the absence of IL-2. A CD8(+) T cell clone, when transduced with an IL-2 gene, manifested the same phenotypes as PBMCs in the absence of exogenous IL-2. Furthermore, an Ab reactive with the alpha -chain of IL-2R complex reduced the viability mediated by IL-2 secretion of the IL-2 transductants. Moreover, transduction of an IL-2 gene did not affect the high degree of recognition and specificity of transductants against melanoma targets. These tumor-reactive IL-2 transductants may be valuable for in vitro studies and for improved adoptive transfer therapies for patients with metastatic melanoma.
引用
收藏
页码:6356 / 6365
页数:10
相关论文
共 50 条
  • [1] Transduction of an interleukin-2 (IL2) gene into human melanoma reactive lymphocytes results in their continued growth in the absence of exogenous IL2 and maintains their specific antitumor activity.
    Liu, K
    Rosenberg, SA
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3755S - 3755S
  • [2] Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent
    Liu, K
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (03): : 190 - 201
  • [3] INTERLEUKIN 2 (IL-2) ACTIVITY DURING TUMOR-GROWTH - IL-2 PRODUCTION KINETICS, ABSORPTION OF AND RESPONSES TO EXOGENOUS IL-2
    BURGER, CJ
    ELGERT, KD
    FARRAR, WL
    CELLULAR IMMUNOLOGY, 1984, 84 (02) : 228 - 239
  • [4] CHEMOATTRACTANT ACTIVITY OF IL-2 FOR HUMAN-LYMPHOCYTES - A REQUIREMENT FOR THE IL-2 RECEPTOR BETA-CHAIN
    WILKINSON, PC
    NEWMAN, I
    IMMUNOLOGY, 1994, 82 (01) : 134 - 139
  • [5] IL-2 and IL-12 increase gene transduction by recombinant adenovirus into primary human lymphocytes.
    Di Nicola, M
    Bregni, M
    Milanesi, M
    Longoni, P
    Matteucci, P
    Siena, S
    Jordan, CT
    Gianni, AM
    BONE MARROW TRANSPLANTATION, 1998, 21 : S111 - S111
  • [6] STRATEGIES FOR IMPROVING ANTITUMOR-ACTIVITY UTILIZING IL-2 - PRECLINICAL MODELS AND ANALYSIS OF ANTITUMOR-ACTIVITY OF LYMPHOCYTES FROM PATIENTS RECEIVING IL-2
    ALBERTINI, MR
    HANK, JA
    SONDEL, PM
    BIOTHERAPY, 1992, 4 (03) : 189 - 198
  • [7] Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
    Carmenate, Tania
    Pacios, Anabel
    Enamorado, Michel
    Moreno, Ernesto
    Garcia-Martinez, Karina
    Fuente, Dasha
    Leon, Kalet
    JOURNAL OF IMMUNOLOGY, 2013, 190 (12): : 6230 - 6238
  • [8] IL-2 RECEPTOR INDUCTION ON HUMAN LYMPHOCYTES-T - ROLE FOR IL-2 AND MONOCYTES
    WAKASUGI, H
    BERTOGLIO, J
    TURSZ, T
    FRADELIZI, D
    JOURNAL OF IMMUNOLOGY, 1985, 135 (01): : 321 - 327
  • [9] 2 REGIONS WITHIN THE HUMAN IL-2 GENE PROMOTER ARE IMPORTANT FOR INDUCIBLE IL-2 EXPRESSION
    WILLIAMS, TM
    EISENBERG, L
    BURLEIN, JE
    NORRIS, CA
    PANCER, S
    YAO, D
    BURGER, S
    KAMOUN, M
    KANT, JA
    JOURNAL OF IMMUNOLOGY, 1988, 141 (02): : 662 - 666
  • [10] Maintenance interleukin-2 (IL-2) and sargramostim (GM-CSF) following high-dose IL-2 (HD IL-2) therapy for metastatic melanoma
    Chu, Melinda Bernabe
    Fesler, Mark
    Armbrecht, Eric
    Fosko, Scott
    Hsueh, Eddy C.
    Richart, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)